ArticleLeukemia & lymphoma2013

Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.

Jeffrey A Jones et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.